In vivo kinetics and biodistribution of HB-110, a novel HBV DNA vaccine, after administration in mice
SCIE
SCOPUS
KCI
- Title
- In vivo kinetics and biodistribution of HB-110, a novel HBV DNA vaccine, after administration in mice
- Authors
- Kang, ES; Kim, CY; Kim, SB; Im, SJ; Yang, SH; Sung, YC; Kim, BM
- Date Issued
- 2007-03
- Publisher
- PHARMACEUTICAL SOCIETY KOREA
- Abstract
- This study investigated the pharmacokinetic profile and biodistribution of HB-110, a novel HBV therapeutic vaccine candidate, in mice. HB-110 was rapidly degraded in the blood after i.v. injection with a half-life of 1.9 +/- 0.083 min, and was no longer detected at 60 min except in one individual near the detection limit. In the i.m. injection, plasmid DNA was detectable at the injection site until 11 days after administration, but the amounts were just above the detection limit. The blood concentration of HB-110 showed a maximum of 604 pg/mL at 15 min after i.m. injection, which was followed by degradation to undetectable levels at 90 min. The plasmid DNA in tissues peaked at 90 min after administration. The highest concentration of plasmid DNA was detected in the liver (24.172 pg/mg tissue), and considerable amounts were also observed in the lung (9.467 pg/mg tissue) and spleen (7.688 pg/mg tissue). The amount of plasmid DNA in tissues was 2 to 3 orders of magnitude lower than in the injection site at the same time points. The HB-110 concentration in tissues, including gonads, decreased rapidly and was undetectable 24 In after administration.
- Keywords
- HB-110; HBV; plasmid DNA vaccine; in vivo kinetics; biodistribution; CHRONIC HEPATITIS-B; PLASMID DNA; LAMIVUDINE THERAPY; VIRUS; PHARMACOKINETICS; INJECTION
- URI
- https://oasis.postech.ac.kr/handle/2014.oak/23496
- DOI
- 10.1007/BF02977618
- ISSN
- 0253-6269
- Article Type
- Article
- Citation
- ARCHIVES OF PHARMACAL RESEARCH, vol. 30, no. 3, page. 355 - 360, 2007-03
- Files in This Item:
- There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.